agilon health Inc (AGL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at agilon health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 94.10 $ — 72% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 39.8%
- Exp. sales growth 3Y > 5% 1.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 1.2%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -664.4%
- ROCE > 15% -216.2%
- Expected return > 10% -6.3%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 35.4% passed
- More than 10% revenue growth is expected for the coming year 6.3% failed
- Share count grows by less than 3% a year 0.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -4.1% failed
- Gross margin at 40% or higher and without meaningful erosion -3.2% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 248 m net cash passed
- Operating cash flow covers the profits of the last three years 608 m failed
- Return on capital at 15% or higher, or up versus two years ago -216.2% failed
- Insiders hold at least 10% or are net buyers 3.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 17.0% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 20
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.88 | -7.02 – 0.09 | 5,719 | 87.9% | 12 |
| 12/31/2027 | -1.03 | -4.52 – 2.06 | 6,079 | 61.2% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.06 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -6.42 | – | 1,523 | 86.70 | -6.90 | 16 | 4 |
| 2025: Q1 | 0.73 | – | 1,533 | -4.50 | 0.80 | -32 | -43 |
| 2025: Q2 | -6.31 | – | 1,395 | -5.90 | -7.50 | -35 | -38 |
| 2025: Q3 | -6.65 | – | 1,435 | -1.10 | -7.70 | -18 | -21 |
| 2025: Q4 | -11.39 | – | 1,570 | 3.10 | -12.00 | -21 | -38 |
| 2026: Q1 | 1.80 | 145.30 | 1,421 | -7.30 | 2.10 | 24 | 21 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 794 | -107 | -283 | -18.40 | -104 | -232 | 403 |
| 2020 | 1,218 | -57 | -60 | -3.90 | -53 | -285 | 446 |
| 2021 | 1,521 | -372 | -406 | -27.25 | -148 | 1,092 | 1,586 |
| 2022 | 2,388 | -105 | -107 | -6.53 | -131 | 1,041 | 1,697 |
| 2023 | 4,316 | -232 | -263 | -16.05 | -156 | 662 | 1,741 |
| 2024 | 6,061 | -292 | -260 | -15.83 | -58 | 471 | 1,734 |
| 2025 | 5,933 | -421 | -405 | -24.48 | -106 | 127 | 1,271 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
agilon health, inc. bietet Gesundheitsdienstleistungen für Senioren über Hausärzte in den Gemeinden der USA an.
| Employees | 856 |
|---|---|
| Headquarters | Westerville, OH |
| Address | 440 Polaris Parkway, 43082 Westerville, United States |
| Phone | 562 256 3800 |
| Website | agilonhealth.com |
| IPO Date | 15. Apr 2021 |
| ISIN | US00857U2069 |
| Stock Split | 1:25 on 03/31/2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey Alan Schwaneke CPA | Executive VP & CFO | 1976 |
| Denise Zamore | Chief Legal Officer & Secretary | 1975 |
| Benjamin Shaker | Chief Markets Officer | 1983 |
| Timothy Patrick O'Rourke | CEO & Director | – |
| Timothy Gertsch | Chief Accounting Officer | 1987 |
| Evan Smith C.F.A. | Senior Vice President of Investor Relations | – |
| Bill Farry | Chief of Technology Innovation | – |
| Kenny Bellendir | Markets Chief Financial Officer | – |
| Heidi Hittner | Chief Business Operations Officer | – |
| Karthik Rao M.D. | Chief Medical Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.